Peer-reviewed veterinary case report
Drug-resistant Babesia gibsoni in dogs treated with atovaquone
By Sakuma, M et al.·Published in Journal of veterinary internal medicine·2009·Faculty of Agriculture, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin.
- Species:
- dog
Plain-English summary
Eight dogs infected with Babesia gibsoni, a parasite that can cause serious illness, were treated with a combination of atovaquone and azithromycin. All the dogs showed quick improvement in their health and blood tests after starting treatment. However, five of the dogs experienced a relapse of their symptoms after the treatment ended, suggesting that drug-resistant variants of the parasite may have developed. While this combination therapy can be effective, pet owners should be aware of the possibility of relapses and discuss ongoing monitoring with their veterinarian.
People also search for: dog Babesia gibsoni treatment · dog parasite infection symptoms · atovaquone azithromycin for dogs
Abstract
BACKGROUND: There is no well-established treatment strategy for Babesia gibsoni infection. A new therapeutic protocol using atovaquone (ATV) and azithromycin (AZM) has been proposed, but there is concern about the possible induction of relapse and the emergence of ATV-resistant variants after treatment. OBJECTIVE: To evaluate the clinical use of combination therapy with ATV and AZM as a first-line treatment of clinical B. gibsoni infection in dogs, and to investigate the emergence of ATV-resistant variants. ANIMALS: Eight B. gibsoni naturally infected dogs showing signs of acute onset of disease. METHODS: Retrospective case study. Eight clinical cases received combination therapy with ATV and AZM at Kagoshima University Veterinary Teaching Hospital during 2007-2008, and their clinical courses and clinicopathological parameters were evaluated. In addition, alterations in the cytochrome b (CYTb) gene of B. gibsoni were analyzed by polymerase chain reaction and DNA sequencing techniques. RESULTS: All of the dogs responded well to the treatment, with rapid improvement in their clinical condition and hematological parameters. However, 5 of the 8 dogs relapsed after treatment. Analysis of the CYTb gene strongly suggested the emergence of ATV-resistant variants after treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: The combination of ATV and AZM can be used as a first-line treatment for dogs with babesiosis, but relapses occur. Attention should be paid to the possible in vivo selection of drug-resistant variants.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19645835/